Differential Contribution of Nitric Oxide and cGMP to the Stimulatory Effects of Growth Hormone-Releasing Hormone and Low-Concentration Somatostatin on Growth Hormone Release from Somatotrophs

• Published in: Journal of neuroendocrinology 2005-09, Vol.17 (9), p.577-582
• Main Authors: Luque, R. M., Rodríguez-Pacheco, F., Tena-Sempere, M., Gracia-Navarro, F., Malagón, M. M., Castaño, J. P.
• Format: Article
• Language: English
• Subjects: Animals; Biological and medical sciences; Cells, Cultured; Cyclic GMP - analogs & derivatives; Cyclic GMP - pharmacology; Cyclic GMP - physiology; Enzyme Inhibitors - pharmacology; Female; Fundamental and applied biological sciences. Psychology; GH secretion; GHRH/somatostatin; Growth Hormone-Releasing Hormone - pharmacology; Guanylate Cyclase - antagonists & inhibitors; guanylyl cyclase/cGMP; Hormone Antagonists - pharmacology; Indicators and Reagents; Nitric Oxide - physiology; NOS/NO; pig pituitary somatotrophs; Pituitary Gland - cytology; Pituitary Gland - drug effects; Pituitary Gland - metabolism; Somatostatin - pharmacology; Swine; Vertebrates: endocrinology
• ISSN: 0953-8194; 1365-2826
• DOI: 10.1111/j.1365-2826.2005.01345.x

There is increasing evidence that nitric oxide (NO) produced by NO synthase (NOS), and their signalling partners, guanylyl cyclase and cGMP, play a relevant role in growth hormone (GH) secretion from somatotrophs. We previously demonstrated that both GH‐releasing hormone (GHRH; 10−8 M) and low concentrations of somatostatin (10−15 M) stimulate pig GH release in vitro, whereas a high somatostatin concentration (10−7 M) inhibits GHRH‐induced GH secretion. To ascertain the possible contribution of the NOS‐NO and guanylyl cyclase‐cGMP routes to these responses, cultures of pituitary cells from prepubertal female pigs were treated (30 min) with GHRH (10−8 M) or somatostatin (10−7 or 10−15 M) in the absence or presence of activators or blockers of key steps of these signalling cascades, and GH release was measured. Two distinct activators of NO route, SNAP (5 × 10−4 M) or L‐AME (10−3 M), similarly stimulated GH release when applied alone (with this effect being blocked by 10−7 M somatostatin), but did not alter the stimulatory effect of GHRH or 10−15 M somatostatin. Conversely, two NO pathway inhibitors, NAME (10−5 M) or haemoglobin (20 µg/ml) similarly blocked GHRH‐ or 10−15 M somatostatin‐stimulated GH release. 8‐Br‐cGMP (10−8 to 10−4 M) strongly stimulated GH release, suggesting that cGMP may function as a subsequent step in the NO pathway in this system. Interestingly, 10−7 M somatostatin did not inhibit the stimulatory effect of 8‐Br‐cGMP. Moreover, although 8‐Br‐cGMP did not modify the effect of GHRH, it enhanced GH release stimulated by 10−15 M somatostatin. Accordingly, a specific guanylyl cyclase inhibitor, LY‐83, 583 (10−5 M) did not alter 10−15 M somatostatin‐induced GH release, whereas it blocked GHRH‐induced GH secretion. These results demonstrate for the first time that the NOS/NO signalling pathway contributes critically to the stimulatory effects of both GHRH and low‐concentration somatostatin on GH release, and that, conversely, the subsequent guanylyl cyclase/cGMP step only mediates GHRH‐ and not low‐concentration somatostatin‐induced GH secretion from somatotrophs.